PMID- 32547087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 13
DP  - 2020
TI  - LncRNA SNHG16 Promotes the Progression of Laryngeal Squamous Cell Carcinoma by 
      Mediating miR-877-5p/FOXP4 Axis.
PG  - 4569-4579
LID - 10.2147/OTT.S250752 [doi]
AB  - OBJECTIVE: Laryngeal cancer is a common malignant tumor in the ENT, of which 
      laryngeal squamous cell carcinoma (LSCC) accounts for more than 90% of laryngeal 
      cancer. The purpose of this study is to investigate the regulatory mechanism of 
      lncRNA SNHG16 in LSCC. MATERIALS AND METHODS: Real-time quantitative reverse 
      transcription polymerase chain reaction (RT-qPCR) was used to measure mRNA 
      expression. Cell Counting Kit (CCK-8), Transwell and luciferase reporter assays, 
      flow cytometric analysis and Western blot analysis were used to investigate the 
      function of lncRNA SNHG16 in LSCC. RESULTS: SNHG16 expression was increased in 
      LSCC tissues and cells. The abnormal expression of SNHG16 was associated with 
      clinical stage and lymph node metastasis in LSCC patients. In addition, knockdown 
      of SNHG16 restrained cell proliferation, migration and invasion in LSCC. More 
      importantly, SNHG16 acted as a competitive endogenous RNA in LSCC and regulated 
      FOXP4 expression by making miR-877-5p sponge. Further, SNHG16 promoted LSCC 
      progression by interacting with miR-877-5p and FOXP4. CONCLUSION: LncRNA SNHG16 
      promotes the progression of LSCC by sponging miR-877-5p and upregulating FOXP4.
CI  - (c) 2020 Wang et al.
FAU - Wang, Xiaoli
AU  - Wang X
AD  - Department of Clinical Laboratory, Jinan City People's Hospital, Jinan People's 
      Hospital Affiliated to Shandong First Medical University, Jinan 271199, People's 
      Republic of China.
FAU - Liu, Liming
AU  - Liu L
AD  - Department of Otorhinolaryngology, Juye County Hospital of TCM, Heze 274900, 
      People's Republic of China.
FAU - Zhao, Wenfei
AU  - Zhao W
AD  - Department of Comprehensive Oncology Therapy, Qingdao Central Hospital, Qingdao 
      University, Qingdao 266043, People's Republic of China.
FAU - Li, Qingyan
AU  - Li Q
AD  - Department of Clinical Laboratory, The People's Hospital of Zhangqiu Area, Jinan 
      250200, People's Republic of China.
FAU - Wang, Guangsheng
AU  - Wang G
AD  - Department of Neurology, The People's Hospital of Zhangqiu Area, Jinan 250200, 
      People's Republic of China.
FAU - Li, Huahui
AU  - Li H
AD  - Department of Clinical Laboratory, Qingdao Municipal Hospital, Qingdao 266071, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC7251222
OTO - NOTNLM
OT  - FOXP4
OT  - SNHG16
OT  - laryngeal squamous cell carcinoma
OT  - miR-877-5p
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/22
CRDT- 2020/06/18 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/22 00:00 [pmc-release]
AID - 250752 [pii]
AID - 10.2147/OTT.S250752 [doi]
PST - epublish
SO  - Onco Targets Ther. 2020 May 22;13:4569-4579. doi: 10.2147/OTT.S250752. 
      eCollection 2020.